Loading…
← CockpitCompetitor Analysis › 2664.T Cawachi LimitedOpen in the cockpit ↗

Cawachi Limited2664.TCompetitor analysis, valuation and peers

Japan · JPY·Consumer Staples›Drugstore Chains
Momentum leader 87
Mkt cap
$562M
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$2.01M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+0.2 pp
WACC 5.0%
Hurdle
-6 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · JPY¥4,010
1D-2.0%
1W-1.0%
1M-0.7%
3M+6.4%
6M+30.8%
YTD+33.7%
1Y+35.0%
ATR %2.5%
52w lowhigh4.8% off high

What Cawachi does

Employees: 2,750

Cawachi at a glance

Size Cawachi (2664.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $562M, the 1002nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,010 on 18 Nov 2026.

Performance Over six months the shares gained 30.8%, against -16.8% for the median peer and -1.4% for the Japan market (cap-weighted) — highest of 15 in its peer set.

Growth Revenue fell 0.9% over the last twelve months (peer median +6.5%); the operating margin is 2.3% (peer median 4.3%).

Valuation It trades at 0.2× enterprise value to sales against a peer median of 0.8× (cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -6 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.2 points above its cost of capital (5.0% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 20262664.T 132Peer median 83
Six months, rebased to 100: Cawachi against the median of its 14 peers (local-currency closes).

Cawachi financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥283B¥284B¥288B¥286B¥282B
Revenue growth—-1%+1%+1%—
Gross profit¥65.1B¥60.9B¥62.3B¥61.5B¥59.7B
EBITDA¥11.0B¥11.2B¥11.9B¥11.9B¥10.9B
Net income¥2.99B¥3.20B¥4.88B¥4.71B¥4.18B
Free cash flown/a¥4.66B¥3.40B¥1.57B¥4.57B
Capital expendituren/a¥4.45B¥4.31B¥5.42B¥5.71B
Total debt¥15.0B¥16.1B¥16.6B¥16.7B¥19.5B

Quarterly statements and history in the cockpit →

Cawachi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%30346035900027883010179267301408MEDPLUS00050460083360526600272796276038832664.T6-month return →1-month return →
Up and to the right = strong over both horizons. Cawachi is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×2×4×30346035900027883010173014080005046008332664.TRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cawachi is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%0%20%3034603590002788301017301408MEDPLUS600833605266002727962731486038832664.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cawachi is the large dot.

Cawachi competitors and peer comparison

How Cawachi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cawachi against its 14 peers (data as of 18 Nov 2026)
Measure2664.TPeer medianRank in peer set
1-month return-0.7%-5.7%7th highest of 15
6-month return+30.8%-16.8%highest of 15
Distance from 52-week high-4.8%-41.8%highest of 15
Revenue growth (TTM)-0.9%+6.5%3rd lowest of 15
Operating margin2.3%4.3%5th lowest of 15
EV / Sales0.2×0.8×cheapest of 15
Growth the price implies (Req g, 7 yrs)-6.1%-7.0%6th most demanding of 13
Growth delivered (Del g)0.0%+11.1%lowest of 13
Hurdle (Req g minus delivered)-6.1 pp-20.0 pp4th most demanding of 13
ROIC minus cost of capital+0.2 pp+2.6 pp5th lowest of 15
Net debt / EBITDA-2.4×1.5×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cawachi 2664.TJapan$562M+31%-1%2%0.2×-6.1%0.0%
Qol 3034.TJapan$561M+26%+5%6%0.4×-16.6%+12.4%
Beijing Konruns Pharmaceutical 603590.SSChina$558M-33%-1%17%4.2×12.4%+2.7%
Luyan Pharma 002788.SZChina$514M-32%+3%3%0.4×-0.4%+6.5%
Shu Yu Civilian Pharmacy 301017.SZChina$701M-11%+9%2%0.8×1.1%+17.4%
Genky DrugStores 9267.TJapan$728M+3%+8%5%0.6×n/an/a
Anhui Huaren Health Pharmaceutical 301408.SZChina$745M-32%+15%8%1.1×-7.5%+23.3%
MedPlus Health Services MEDPLUS.NSIndia$771M-36%+21%4%1.1×18.6%+17.6%
Landfar Bio-medicine 000504.SZChina$351M-22%+497%-2%3.1×n/an/a
Shanghai No. 1 Pharmacy 600833.SSChina$299M-22%+1%-1%0.9×19.5%+6.1%
JZJ Chain Drugstore Corporation 605266.SSChina$293M-35%-5%0%0.7×-9.9%+14.8%
Yixintang Pharmaceutical 002727.SZChina$1.16B+4%-2%3%0.5×-16.0%+6.5%
Ain 9627.TJapan$1.25B+2%+42%4%0.5×-6.5%+16.9%
Create SD 3148.TJapan$1.32B+3%+9%5%0.3×-11.5%+8.0%
LBX Pharmacy Chain Joint Stock 603883.SSChina$1.71B+13%+3%5%0.8×-10.7%+9.7%

Questions

Which companies are Cawachi's closest peers?
The cockpit's peer set: Qol (3034.T), Beijing Konruns Pharmaceutical (603590.SS), Luyan Pharma (002788.SZ), Shu Yu Civilian Pharmacy (301017.SZ), Genky DrugStores (9267.T), Anhui Huaren Health Pharmaceutical (301408.SZ), MedPlus Health Services (MEDPLUS.NS), Landfar Bio-medicine (000504.SZ).
Is Cawachi expensive compared with its peers?
On ev / sales it trades at 0.2× against a peer median of 0.8×, cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -6 pp: the price already allows for a slowdown.
How has Cawachi stock performed?
Over six months to 18 Nov 2026 the shares returned +30.8% against -16.8% for the median peer; over one year +35.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.